Roginolisib hemifumarate（MSC2360844 hemifumarate）是一种口服有效的选择性PI3Kδ抑制剂。该化合物对包含278种激酶的筛选面板表现出高度选择性，显示出良好的靶向特异性。

/

2~8℃避光保存，有效期3年。

[1] Haselmayer P, Camps M, Muzerelle M, El Bawab S, Waltzinger C, Bruns L, Abla N, Polokoff MA, Jond-Necand C, Gaudet M, Benoit A, Bertschy Meier D, Martin C, Gretener D, Lombardi MS, Grenningloh R, Ladel C, Petersen JS, Gaillard P, Ji H. Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies. Front Immunol. 2014 May 22;5:233. doi: 10.3389/fimmu.2014.00233. PMID: 24904582; PMCID: PMC4033217.